Published Date: 08 Mar 2023
The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Ketamine plus psychotherapy for "excellent" PTSD
2.
Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.
3.
Having a tattoo could increase your risk of developing lymphoma.
4.
New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada
5.
Males with early-onset colorectal cancer are at risk, according to a study.
1.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
2.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
3.
Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans
4.
Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management
5.
The latest Hematocrit: An Overview of Red Blood Cell Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
3.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
4.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation